NASDAQ:INM InMed Pharmaceuticals - INM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.20 +0.12 (+5.77%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.85▼$2.2450-Day Range$1.32▼$2.7452-Week Range$1.23▼$35.50Volume477,684 shsAverage Volume866,755 shsMarket Capitalization$2.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About InMed Pharmaceuticals (NASDAQ:INM) StockInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Read More Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INM Stock News HeadlinesJanuary 11, 2023 | benzinga.comThis Company's Rare Cannabinoids May Hold Promise In The Treatment Of Neurodegenerative Diseases Like Alzheimer'sJanuary 2, 2023 | marketwatch.comBiosynthesis of Cannabinoids Market Size and Share Likely to Grow with CAGR Status and Industry Revenue Forecast by 2023-2029February 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 15, 2022 | finance.yahoo.comInMed Announces Results of 2022 Annual General MeetingNovember 18, 2022 | marketwatch.comInMed Pharmaceuticals Shares Drop 19% After Private Placement PricesNovember 17, 2022 | finance.yahoo.comInMed Provides Update on Management ChangesNovember 16, 2022 | marketwatch.comInMed Pharmaceuticals Shares Rise on New Cannabinoid Study on Neurodegenerative DiseasesNovember 16, 2022 | finance.yahoo.comInMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant FundingFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 10, 2022 | finance.yahoo.comRegistration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022October 26, 2022 | finance.yahoo.comInMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness WeekSeptember 19, 2022 | finance.yahoo.comInMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022September 14, 2022 | marketwatch.comInMed Pharmaceuticals Shares Drop After Monday RiseSeptember 12, 2022 | seekingalpha.comInMed adds 63% on rising volume after private placementSeptember 12, 2022 | markets.businessinsider.comS&P 500 Rises 1%, InMed Pharmaceuticals Shares Spike HigherSeptember 12, 2022 | msn.comWhy InMed Pharmaceuticals Stock Is Rising TodaySeptember 9, 2022 | seekingalpha.comInMed climbs 23% amid plans to focus on pharma drug developmentJuly 25, 2022 | msn.comInMed Provides An Update On Phase 2 Clinical Trial Investigating Cannabinol Cream For Epidermolysis BullosaJune 9, 2022 | baystreet.caTop 5 Ways to Profit from a Potential THCV BoomJune 2, 2022 | seekingalpha.comInMed Pharmaceuticals announces $5M registered direct and private placement offeringsJune 2, 2022 | finance.yahoo.comInMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq RulesMay 17, 2022 | realmoney.thestreet.comInMed Pharmaceuticals Inc. (INM)May 13, 2022 | finance.yahoo.comInMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business UpdateMay 13, 2022 | finance.yahoo.comInMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue EstimatesMay 13, 2022 | benzinga.comInMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica AcquisitionMay 5, 2022 | ca.finance.yahoo.comStocks in play: InMed Pharmaceuticals IncMay 3, 2022 | uk.investing.comInMed Pharmaceuticals: Notable Launches Of High-Value Rare CannabinoidsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INM Company Calendar Last Earnings11/11/2022Today2/05/2023Next Earnings (Estimated)2/13/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INM CUSIPN/A CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($30.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,600,000.00 Net Margins-1,356.41% Pretax Margin-1,355.85% Return on Equity-169.59% Return on Assets-123.00% Debt Debt-to-Equity Ratio0.03 Current Ratio3.52 Quick Ratio2.98 Sales & Book Value Annual Sales$1.09 million Price / Sales1.90 Cash FlowN/A Price / Cash FlowN/A Book Value$13.95 per share Price / Book0.16Miscellaneous Outstanding Shares940,000Free Float915,000Market Cap$2.07 million OptionableNot Optionable Beta-0.24 Key ExecutivesMr. Eric A. Adams B.S. Chem. (Age 60)M.I.B., Pres, CEO & Director Comp: $363.17kMs. Alexandra Diane-Janet Mancini M.Sc. (Age 70)Sr. VP of Clinical & Regulatory Affairs Comp: $261.03kDr. Eric Chih-Hsien Hsu (Age 53)Sr. VP of Preclinical R&D Comp: $253.46kDr. Sazzad Hossain M.Sc. (Age 65)Ph.D., Co-Founder Mr. Jonathan R. Tegge (Age 33)Interim Chief Financial Officer Mr. Michael Woudenberg P.Eng. (Age 54)Chief Operating Officer Ms. Sarah Li CPACGA, VP of Accounting & ControllerColin ClancySr. Director of Investor RelationsMr. Jerry P. GriffinVP of Sales & MarketingDr. Shane A. Johnson Ph.D.Sr. VP & GM of BayMedicaMore ExecutivesKey CompetitorsCalithera BiosciencesNASDAQ:CALAStatera BiopharmaNASDAQ:STABAltamira TherapeuticsNASDAQ:CYTOChina SXT PharmaceuticalsNASDAQ:SXTCPanbela TherapeuticsNASDAQ:PBLAView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 866,118 shares on 11/14/2022Ownership: 9.605%UBS Group AGBought 5,797 shares on 11/10/2022Ownership: 0.617%Eric A AdamsBought 8,560 shares on 4/13/2022Total: $7,276.00 ($0.85/share)View All Insider TransactionsView All Institutional Transactions INM Stock - Frequently Asked Questions Should I buy or sell InMed Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INM, but not buy additional shares or sell existing shares. View INM analyst ratings or view top-rated stocks. How have INM shares performed in 2023? InMed Pharmaceuticals' stock was trading at $2.02 at the beginning of the year. Since then, INM shares have increased by 8.9% and is now trading at $2.20. View the best growth stocks for 2023 here. When is InMed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023. View our INM earnings forecast. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its earnings results on Friday, November, 11th. The company reported ($4.06) EPS for the quarter, beating analysts' consensus estimates of ($4.25) by $0.19. The business earned $0.32 million during the quarter. InMed Pharmaceuticals had a negative net margin of 1,356.41% and a negative trailing twelve-month return on equity of 169.59%. When did InMed Pharmaceuticals' stock split? Shares of InMed Pharmaceuticals reverse split on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is InMed Pharmaceuticals' stock symbol? InMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "INM." How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is InMed Pharmaceuticals' stock price today? One share of INM stock can currently be purchased for approximately $2.20. How much money does InMed Pharmaceuticals make? InMed Pharmaceuticals (NASDAQ:INM) has a market capitalization of $2.07 million and generates $1.09 million in revenue each year. The company earns $-18,600,000.00 in net income (profit) each year or ($30.98) on an earnings per share basis. How can I contact InMed Pharmaceuticals? The official website for the company is www.inmedpharma.com. The company can be reached via phone at 604-669-7207 or via email at info@inmedpharma.com. This page (NASDAQ:INM) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.